CANNAINVESTOR Magazine August / September 2017 | Page 166

ABcann amended and extended the research contract in place with the University of Guelph . The ongoing research is focused on the controlled environment production of medicinal cannabis and has become a contributing factor to increasing yields and a higher quality , pesticide free standardized product .
ABcann welcomed two new additional advisors in Prof . Raphael Mechoulam and W . Brett Wilson . The Company also appointed Dr . Michael Shannon as its chief medical consultant .
Subsequent to June 30 , 2017 :
ABcann was included in the Horizons Medical Marijuana Life Sciences ETF . The ETF offers investors direct exposure to a basket of North American publicly listed companies that meet minimum asset and liquidity thresholds .
Additional listings on both the OTCQB Marketplace ( ABCCF ) and FSE , the Frankfurt Stock Exchange ( 23Q ) were obtained .
The Company completed a private placement financing of common shares to CBW at a price of $ 2.25 per share for proceeds of $ 15m .
The Company received approximately $ 7.5m in additional proceeds from the exercises of nearly 12m warrants issued in connection with 2014 and 2015 private placements . These warrants were to expire on September 9 , 2017 .
About ABcann Global Corporation ( TSX . V : ABCN ) :
ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations , which it received on March 21 , 2014 . It obtained a sales license on December 31 , 2015 . ABcann ’ s flagship facility in Napanee , Ontario utilizes proprietary plant-growing technology , including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process . This approach and the systems in place allow ABcann to produce organically grown and pesticide-free , high-yielding plants , which , in turn , can generate high-quality products that are consistent from batch to batch . ABcann is able to control environmental and nutrient demands , tailor-made for a particular strain of cannabis , without the variation that is typical when producing large quantities in lesscontrolled , larger rooms and greenhouse-type structures . ABcann ’ s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product .
ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking its expansion into a new 150,000 sq ft facility in Napanee . ABcann is pursuing opportunities in Germany , Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles .

166